tetano
Editor, Senior Moderator
Sci Rep. 2018 Mar 12;8(1):4374. doi: 10.1038/s41598-018-22307-8.
[h=1]A Highly Potent and Broadly Neutralizing H1 Influenza-Specific Human Monoclonal Antibody.[/h] Nogales A[SUP]1[/SUP], Piepenbrink MS[SUP]2[/SUP], Wang J[SUP]3[/SUP], Ortega S[SUP]1[/SUP], Basu M[SUP]2[/SUP], Fucile CF[SUP]4[/SUP], Treanor JJ[SUP]2[/SUP], Rosenberg AF[SUP]4[/SUP], Zand MS[SUP]3[/SUP], Keefer MC[SUP]2[/SUP], Martinez-Sobrido L[SUP]5[/SUP], Kobie JJ[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza's propensity for antigenic drift and shift, and to elicit predominantly strain specific antibodies (Abs) leaves humanity susceptible to waves of new strains with pandemic potential for which limited or no immunity may exist. Subsequently new clinical interventions are needed. To identify hemagglutinin (HA) epitopes that if targeted may confer universally protective humoral immunity, we examined plasmablasts from a subject that was immunized with the seasonal influenza inactivated vaccine, and isolated a human monoclonal Ab (mAb), KPF1. KPF1 has broad and potent neutralizing activity against H1 influenza viruses, and recognized 83% of all H1 isolates tested, including the pandemic 1918 H1. Prophylactically, KPF1 treatment resulted in 100% survival of mice from lethal challenge with multiple H1 influenza strains and when given as late as 72 h after challenge with A/California/04/2009 H1N1, resulted in 80% survival. KPF1 recognizes a novel epitope in the HA globular head, which includes a highly conserved amino acid, between the Ca and Cb antigenic sites. Although recent HA stalk-specific mAbs have broader reactivity, their potency is substantially limited, suggesting that cocktails of broadly reactive and highly potent HA globular head-specific mAbs, like KPF1, may have greater clinical feasibility for the treatment of influenza infections.
PMID: 29531320 DOI: 10.1038/s41598-018-22307-8
Free full text
[h=1]A Highly Potent and Broadly Neutralizing H1 Influenza-Specific Human Monoclonal Antibody.[/h] Nogales A[SUP]1[/SUP], Piepenbrink MS[SUP]2[/SUP], Wang J[SUP]3[/SUP], Ortega S[SUP]1[/SUP], Basu M[SUP]2[/SUP], Fucile CF[SUP]4[/SUP], Treanor JJ[SUP]2[/SUP], Rosenberg AF[SUP]4[/SUP], Zand MS[SUP]3[/SUP], Keefer MC[SUP]2[/SUP], Martinez-Sobrido L[SUP]5[/SUP], Kobie JJ[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza's propensity for antigenic drift and shift, and to elicit predominantly strain specific antibodies (Abs) leaves humanity susceptible to waves of new strains with pandemic potential for which limited or no immunity may exist. Subsequently new clinical interventions are needed. To identify hemagglutinin (HA) epitopes that if targeted may confer universally protective humoral immunity, we examined plasmablasts from a subject that was immunized with the seasonal influenza inactivated vaccine, and isolated a human monoclonal Ab (mAb), KPF1. KPF1 has broad and potent neutralizing activity against H1 influenza viruses, and recognized 83% of all H1 isolates tested, including the pandemic 1918 H1. Prophylactically, KPF1 treatment resulted in 100% survival of mice from lethal challenge with multiple H1 influenza strains and when given as late as 72 h after challenge with A/California/04/2009 H1N1, resulted in 80% survival. KPF1 recognizes a novel epitope in the HA globular head, which includes a highly conserved amino acid, between the Ca and Cb antigenic sites. Although recent HA stalk-specific mAbs have broader reactivity, their potency is substantially limited, suggesting that cocktails of broadly reactive and highly potent HA globular head-specific mAbs, like KPF1, may have greater clinical feasibility for the treatment of influenza infections.
PMID: 29531320 DOI: 10.1038/s41598-018-22307-8
Free full text